Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Lymphoma, T-Cell, Peripheral × ivarmacitinib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

OTHER_GOV 1 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE 1 Lymphoma, T-Cell, Peripheral 1

Interventions

Vincristine 2 Prednisone 2 Doxorubicin 2 Cyclophosphamide 2 ivarmacitinib 1 VAP-cyclo protocol 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1 Epirubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05900089 2023-06-12

Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma

Henan Cancer Hospital

Phase 1 Not yet recruiting

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon ⚡